Mauskopf J, Earnshaw SR, Mullins CD, Brogan A. Building a budget impact model: budget impact analysis training. Presented at the 2016 ISPOR Training Courses; November 2016. Durham, NC.
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Cost analysis of Raltegravir versus Atazanavir/r or Darunavir/r for treatment-naive adults with HIV-1 infection in Spain. Poster presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A410.
Earnshaw SR, Brogan AJ, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 20th Annual International Meeting.
Earnshaw SR, Mullins CD, Brogan AJ. Budget impact analysis I: a 6-step approach. Presented at the 2016 ISPOR 19th Annual European Congress; October 30, 2016. Vienna, Austria. Previously presented at the ISPOR 18th Annual European Congress.
Wilkins E, Fisher M, Brogan AJ, Talbird SE, La EM. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial. HIV Med. 2016 Aug;17(7):505-15. doi: 10.1111/hiv.12349
Earnshaw SR, Brogan A, Brodtkorb TH. Budget impact analysis II: applications & design issues. Presented at the 2016 ISPOR 21st Annual International Meeting; May 22, 2016. Washington, DC. Previously presented at the ISPOR 20th Annual International Meeting.
Davis AE, Brogan AJ, Goodwin BB. Cost analysis of raltegravir versus atazanavir/r or darunavir/r for treatment-naive adults with HIV-1 infection in the United States. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A214-5.
Brogan AJ, Mauskopf JA, Quattek K, Jordan J. Lower resource use of 908/ritonavir compared to nelfinavir may be explained by better tolerability. Poster presented at the 42nd Annual Meeting of the Infectious Disease Society of America; October 2004.